Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c
August 5, 2020 4:03 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.16, $0.12 better than the analyst estimate of $0.04. Revenue for the quarter came in at $62.21 million versus the consensus estimate of $61.95 million.
Key Financial and Corporate Highlights
Total revenues from HETLIOZ® and Fanapt® were $62.2 million in the second quarter of... More